Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
- 301/302 Study Group
Research output: Contribution to journal › Article › peer-review
54
Link opens in a new tab
Scopus
citations